ANVS - NYSE
Annovis Bio, Inc.
$2.60
+0.78%Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease in Down Syndrome and other chronic neurodegenerative disorders. It is also developing ANVS405 for protecting the traumatic brain injury and stroke; and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Berwyn, Pennsylvania.
At a Glance
Live Snapshotanvs
Additional Paid-In Capital
Last Annual Value
180.55M
3-Year CAGR
30%
5-Year CAGR
53%
10-Year CAGR
110%
Annovis Bio, Inc. Competitors Analysis of Additional Paid-In Capital
| Company | Additional Paid-In Capital | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
|---|---|---|---|---|---|
Annovis Bio, Inc. NYSE:ANVS | 180.55M | 20.8% | 19.8% | N/A | |
 PDS Biotechnology Corporation NASDAQ:PDSB | 225.84M | 9.8% | 12.8% | 30.1% | |
 Elutia Inc. NASDAQ:ELUT | 203.84M | 14.2% | 11.4% | N/A | |
 MAIA Biotechnology, Inc. AMEX:MAIA | 112.05M | 20.2% | 24.4% | N/A | |
 Actinium Pharmaceuticals, Inc. AMEX:ATNM | 408.55M | 3.0% | 4.4% | 10.2% | |
 BioAtla, Inc. NASDAQ:BCAB | 500.30M | 0.9% | 4.7% | N/A |
Annovis Bio, Inc. Fair Value Envelope
Related Guides
Continue your ANVS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.